Q-omics provides the consensus-scored TMEM263 profile across patient tissues and cancer cell-line models. TMEM263 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMEM263 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, TMEM263 protein abundance shows 26,959 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where TMEM263 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM263 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM263 survival associations across molecular data types. TMEM263 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM263 RNA expression–survival associations across cancer types. High TMEM263 expression shows unfavorable associations in MESO, KIRP, UVM, STAD, LIHC and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMEM263 RNA expression.
This table summarizes TMEM263 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM263. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM263 shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, LUAD, KIRC and COAD. The HNSC box plot shows higher TMEM263 RNA expression in tumor versus normal tissue (log2 FC = +1.467, t-test p < 0.001).
This table shows molecular features associated with TMEM263 in patient tissues and cancer cell lines. In patient samples, TMEM263 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM263 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
